Hodgkin Lymphoma, version 2.2015 Review uri icon

Overview

MeSH Major

  • Hodgkin Disease

abstract

  • Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

authors

publication date

  • May 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4898052

PubMed ID

  • 25964641

Additional Document Info

start page

  • 554

end page

  • 86

volume

  • 13

number

  • 5